Guardant Health and Merck announced a multi‑year collaboration to develop companion diagnostics and commercialize new cancer therapies using Guardant’s Infinity Smart platform.
The partnership will leverage Guardant’s liquid‑biopsy portfolio to support Merck’s oncology programs, providing molecular clarity for patient selection and accelerating drug development timelines. Specific oncology programs or cancer types were not disclosed, but the collaboration is expected to span multiple therapeutic areas.
Guardant’s recent financial performance shows strong revenue growth, with Q4 2025 revenue of $280 million, up 39% YoY, and full‑year 2025 revenue of $981 million, up 33% YoY. The company has raised its 2025 revenue guidance and is improving its operating loss, indicating confidence in scaling its diagnostics business.
The collaboration expands Guardant’s market reach and creates new revenue opportunities, reinforcing its focus on precision oncology. By integrating its Infinity Smart platform into Merck’s drug‑development pipeline, Guardant positions itself as a key partner in the growing companion‑diagnostics market.
Helmy Eltoukhy, Guardant’s chairman and co‑CEO, said the partnership “allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today… ensuring that every trial has the molecular clarity needed to reach the right patients.” The quote underscores Guardant’s commitment to accelerating life‑changing cancer therapies.
The announcement did not disclose upfront payments, milestone or royalty terms, nor a specific timeline for development and commercialization. The partnership is described as multi‑year, indicating a long‑term collaboration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.